Monkey Shortage in China: The Hidden Bottleneck in Drug Research 2026

The monkey shortage in China has become a critical bottleneck in scientific research, driving up costs and threatening the development of new drugs. As the world's second-largest pharmaceutical market, China's reliance on non-human primates for preclinical testing is colliding with a dwindling supply, creating a crisis that could have far-reaching consequences for global health.

At the heart of the issue is a simple economic principle: supply and demand. The demand for monkeys, particularly macaques, has skyrocketed as China's biotech industry shifts toward complex biologics like monoclonal antibodies. These treatments require testing in primates because their biological systems are closer to humans than those of rodents. But the supply has not kept pace, leading to soaring prices and creative accounting.

Why Monkeys Are So Valuable

In August, Joinn Laboratories, China's largest preclinical safety testing company, reported a surprising financial result: it earned more money (747.5 million yuan) than it actually billed (703.8 million yuan). The reason? A revaluation of its "biological assets" added 795 million yuan to its books. In plain terms, those assets are monkeys.

This accounting maneuver highlights the extraordinary appreciation of monkeys in the market. Even if Joinn didn't sell a single monkey, the rising market price allowed it to book a profit. But this raises a more fundamental question: how much is a monkey worth, and why are prices climbing so rapidly?

Public sources indicate that the price of monkeys jumped from 75,000 yuan in May 2025 to 131,000 yuan in March 2026. By June, the National Institutes for Food and Drug Control paid 178,000 yuan per macaque, and in August, the price hit 188,000 yuan. Now, some are asking for over 200,000 yuan—roughly 27,000 euros—per animal.

The Shift to Biologics Drives Demand

Why are monkeys so indispensable? The answer lies in the nature of modern drug development. A significant portion of China's pharmaceutical industry is focused on biologics—large, complex molecules like monoclonal antibodies that are derived from living organisms. These drugs are structurally very similar to human proteins, and their effects can only be accurately assessed in primates.

Rodents, such as mice, are insufficient for testing these biologics because their immune systems and physiology differ markedly from humans. Monkeys, particularly macaques, share enough genetic and biological similarities to provide reliable data on safety and efficacy. As a result, the demand for monkeys has surged in tandem with the boom in China's biotech sector.

The Supply Crunch

On the supply side, the situation is dire. China has strict regulations on the breeding and use of laboratory animals, and monkey breeding is a time-consuming process. It takes years to raise a monkey to the age and size suitable for research, and breeding colonies cannot be scaled up overnight. Moreover, animal welfare concerns and ethical considerations have led to tighter restrictions on the export and import of primates.

Additionally, China has historically been a major supplier of monkeys to global research institutions. But as domestic demand has soared, exports have dwindled, further tightening the global supply. The COVID-19 pandemic exacerbated the shortage, as research into vaccines and treatments increased demand while supply chains were disrupted.

Implications for the Pharmaceutical Industry

The monkey shortage is not just a Chinese problem; it has global ramifications. Many multinational pharmaceutical companies rely on Chinese monkeys for their preclinical trials. As prices rise and availability shrinks, drug development timelines could be delayed, and costs could increase, ultimately affecting patients worldwide.

For Chinese biotech firms, the shortage poses a significant challenge. Startups and smaller companies may struggle to afford the exorbitant prices, potentially stifling innovation. Larger companies might secure supplies through long-term contracts or by acquiring breeding facilities, but this could lead to consolidation in the industry. The longer history behind the story is traced in Wolf Digestion Boosts Blueberry Germination by 96 Percent.

Moreover, the reliance on monkeys for testing biologics raises ethical questions. Animal rights groups argue that the use of primates in research is cruel and unnecessary, and they advocate for alternative methods. However, current regulations in many countries, including China and the US, require primate testing for certain drugs, leaving companies with little choice. The background to this story is set out in Monkeys and Humans: The Bizarre Tortured History Explained. A related thread runs through Abandoned Monkey Found on London Bus: New Law Sparks Fear. Earlier coverage in Abandoned Monkey Found in Laundry Bag on London Bus: New Law shows how the argument developed.

What to Watch Next

The situation is fluid, and several developments could alter the trajectory of the monkey shortage. Here are key factors to monitor: A closer look at the same subject appears in Energy Utilities: latest articles. Anyone following the wider picture can start with China Finds 11,742 Unknown Viruses at 6,000 Meters Deep in Pacific. The same theme surfaces in Vapourware in Aviation: The Airline Industry's Emissions Illusion, which takes a different angle.

• Price trends: Will prices continue to climb, or will they stabilize as new breeding facilities come online?
• Regulatory changes: Could China relax its export restrictions or implement policies to encourage breeding?
• Alternative methods: Advances in organ-on-a-chip technology or other non-animal testing methods could reduce reliance on monkeys.
• Global supply chain: How will other countries, such as the US and EU, respond to the shortage? Will they invest in domestic breeding programs?
• Industry consolidation: Will larger companies acquire smaller ones or breeding facilities to secure supply?

Comparing Primate Testing Requirements

Different regions have varying regulations regarding primate testing for drug approval. The table below summarizes key requirements for major markets. Context on how this played out before sits in Ukraine Strikes Russian Oil Refineries Defying Trump Fuel Warnings. A companion piece, Monkey Shortage in China: The Hidden Bottleneck in Drug Research, approaches the same subject from another angle.

FAQ